Island Pharmaceuticals: Appoints Sofgen for one-off supply of ISLA-101

Island Pharmaceuticals Appoints Sofgen for one-off supply of ISLA-101

  • Island Pharmaceuticals (ILA) executes a one-off proposal with Sofgen for the manufacture of ISLA-101 for the upcoming Phase 2a PEACH clinical trial in dengue infected subjects
  • The new proposal contains a schedule that has ISLA-101 clinical material being manufactured in mid-August, a six-week delay from most recent estimates
  • The company was looking for alternative manufacturers after its prior manufacturer was unable to provide certainty required to plan effectively
  • The new timeline has been consolidated and the company expects the investigational new drug (IND) application to be filed in October with the trial commencing in November
  • Shares in Island Pharmaceuticals are down 18.8 per cent, trading at 13 cents as of 12:01 pm AEST
Steve Sam
Steve Sam
Steve Sam is a financial reporter, analyst, and commentator with a strong focus on banking technology, digital payments, and the future of financial services.

You May Also Like

FundBank Strengthens Position with Acquisition of TRRUE Blockchain Firm

The acquisition enhances FundBank's capabilities in blockchain technology.Highlights: FundBank has acquired the Irish blockchain firm, TRRUE.The acquisition aims...

Visa Strengthens Ties as Anchor Investor in PayPay IPO

Visa commits to supporting PayPay's growth through IPO investment.Highlights: Visa invests as anchor in PayPay's IPO.This move highlights...

Santander and Mastercard Complete Europe’s First Live Agentic AI Transaction

This groundbreaking transaction marks a milestone in AI-driven financial technology.Highlights: Santander and Mastercard execute Europe’s first agentic AI...

Apple Strengthens Reach with Apple Pay Launch in India

Apple Pay expands its footprint, aiming to capture the Indian digital payments market.Highlights: Apple Pay officially launches in...